About NovaMed Pharmaceuticals
NovaMed Pharmaceuticals is a company based in Shanghai (China) founded in 2005 was acquired by SciClone Pharmaceuticals in April 2011. NovaMed Pharmaceuticals has raised $18.8 million across 2 funding rounds from investors including Atlas Venture, SciClone Pharmaceuticals and Eight Roads Ventures.
- Headquarter Shanghai, China
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$18.8 M (USD)
in 2 rounds
-
Latest Funding Round
$13.8 M (USD), Series B
Jan 22, 2008
-
Investors
Atlas Venture
& 2 more
-
Employee Count
Not available
-
Acquired by
SciClone Pharmaceuticals
(Apr 19, 2011)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NovaMed Pharmaceuticals
NovaMed Pharmaceuticals has successfully raised a total of $18.8M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $13.8 million completed in January 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NovaMed Pharmaceuticals
NovaMed Pharmaceuticals has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Atlas Venture, SciClone Pharmaceuticals and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Venture capital investment and global platform support for startups.
|
Locked | Locked | Locked | |
|
Specialty biopharma company that develops and commercializes specialist-oriented drugs
|
Locked | Locked | Locked |
Investor details for NovaMed Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NovaMed Pharmaceuticals
Investment portfolio details for NovaMed Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NovaMed Pharmaceuticals
Detailed financials for NovaMed Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novamed Pharmaceuticals Comparisons
Peer comparison for NovaMed Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NovaMed Pharmaceuticals
Detailed competitors of NovaMed Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novamed Pharmaceuticals
Complete news archive for NovaMed Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NovaMed Pharmaceuticals
NovaMed Pharmaceuticals was founded in 2005 and raised its 1st funding round 2 years after it was founded.
NovaMed Pharmaceuticals is headquartered in Shanghai, China.
NovaMed Pharmaceuticals is a funded company, having raised a total of $18.8M across 2 funding rounds to date.
NovaMed Pharmaceuticals was founded in 2005 and is headquartered in Shanghai, China. The company operates in the pharmaceutical sector, where therapeutics are developed for oncology, cardiovascular disease, central nervous system disorders, urology, and infections. Key products include the broad-spectrum anti-convulsant Depakine, the anti-hypertension ACE inhibitor Tritace, the hypnotic anti-insomnia drug Stilnox, and the interventional cardiology product Aggrastat. Operations focus on research and development in these therapeutic areas.
NovaMed Pharmaceuticals has 3 investors. Key investors include Atlas Venture, SciClone Pharmaceuticals, and Eight Roads Ventures.